Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on [18F]PSMA-11 PET Imaging for Patients with Advanced Thyroid and Head and Neck Cancer

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying two types of cancer: head and neck squamous cell carcinoma and thyroid carcinoma. The treatment being investigated is a special imaging agent called [18F]PSMA-11, which is used in a type of scan known as a PET scan. This agent helps doctors see cancerous lesions more clearly on the scan. The purpose of the study is to see how well this imaging agent works in detecting cancer in patients with advanced forms of these diseases.

Participants in the study will receive an injection of the [18F]PSMA-11 solution, which is administered through a vein. After the injection, a PET scan will be performed to capture images of the cancerous areas. The study aims to observe how much of the imaging agent is taken up by the cancerous lesions, which can help in understanding the extent of the disease. This process will be repeated as needed to gather enough information for the study.

The study will last for a period during which all necessary scans and evaluations will be completed. The results will help determine the effectiveness of [18F]PSMA-11 in providing clear images of cancerous lesions in patients with advanced head and neck squamous cell carcinoma and thyroid carcinoma. This information could be valuable in improving the diagnosis and treatment planning for these types of cancer in the future.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide written informed consent. This means you agree to participate and understand the details of the study.

    You must be at least 18 years old and have at least one measurable lesion of interest that is 1.0 cm or larger on medical imaging.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility and gather baseline information. This may include medical imaging to identify lesions of interest.

  3. Step 3

    Administration of medication

    You will receive an intravenous injection of a solution called [18F]PSMA-11. This is a special type of medication used for imaging purposes.

    The injection is administered directly into your vein, and the process is quick and straightforward.

  4. Step 4

    PET scan

    After the injection, a PET scan will be performed. This scan helps to visualize the uptake of the [18F]PSMA-11 in your body.

    The scan is non-invasive and involves lying still while the machine takes images.

  5. Step 5

    Follow-up assessments

    Follow-up assessments will be conducted to monitor the uptake of the medication in lesions and organs. These assessments are done within 12 months after the last trial-specific intervention.

    The primary goal is to count the lesions with significant uptake, while secondary goals include measuring uptake values in lesions and organs.

  6. Step 6

    Completion of trial

    The trial is expected to be completed by November 24, 2026. All endpoints are measured within 12 months after the last trial-specific intervention.

    You will be informed about the results and any relevant findings from the study.

Who can join the trial?

3 criteria

  • Must be 18 years of age or older.
  • Must be willing and able to provide written informed consent. This means you understand the study and agree to participate.
  • Must have at least one measurable lesion (an area of abnormal tissue) that is at least 1.0 cm in size, as seen on medical imaging like a scan.

Who cannot join the trial?

3 criteria

  • Patients with any other type of cancer besides head and neck squamous cell carcinoma or thyroid carcinoma cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

[18F]AlF-PSMA-11 is a special type of imaging agent used in this clinical trial. It is designed to help doctors see certain types of cancer cells more clearly during a PET scan, which is a type of imaging test. This agent targets a specific protein found on the surface of some cancer cells, particularly in thyroid and head and neck cancers. By highlighting these cells, it helps doctors better understand the extent of the disease and how it is affecting the body. This can be very useful in planning treatment and monitoring how well the treatment is working.

What is already known about the treatment

[18F]AlF-PSMA-11 – This medication is administered through an injection and is used in PET scans to help visualize certain types of cancer, specifically head and neck squamous cell carcinoma and thyroid carcinoma. It is currently being studied in clinical trials to assess its effectiveness in detecting cancerous lesions. The main therapeutic use of [18F]AlF-PSMA-11 is to improve the imaging of cancerous tissues, which can help in diagnosing and planning treatment. At the molecular level, it works by binding to a protein commonly found on the surface of prostate cancer cells, allowing doctors to see these cells more clearly on PET scans. It is classified as a radiopharmaceutical, which means it is a radioactive compound used for diagnosis or treatment.

Investigated diseases

  • Head and Neck Squamous Cell Carcinoma

    This is a type of cancer that originates in the squamous cells lining the moist surfaces inside the head and neck. It typically begins in areas such as the mouth, throat, and nose. The disease progresses as the cancer cells grow and form tumors, which can invade nearby tissues. Over time, it may spread to lymph nodes and other parts of the body. The progression can lead to symptoms like difficulty swallowing, changes in voice, and persistent sore throat. As the disease advances, it can affect breathing and cause significant discomfort.

  • Thyroid Carcinoma

    This is a cancer that starts in the thyroid gland, which is located at the base of the neck. It often begins as a small, painless lump in the thyroid. As the disease progresses, the cancer cells can grow and form larger tumors. These tumors may spread to nearby lymph nodes and other parts of the body. The progression can lead to symptoms such as a noticeable lump in the neck, changes in voice, and difficulty swallowing. Over time, it can cause hormonal imbalances and affect metabolism.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-503036-13-00Protocol codePANTHEON-18Estimated enrolment40 patientsSponsorUniversitair Ziekenhuis Gent

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).